Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes
A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Insulin-Naive Patients With Type 2 Diabetes Mellitus.
Sponsor: Alkermes, Inc.
Listed as NCT00325364, this PHASE3 trial focuses on Diabetes Mellitus, Type 2 and remains completed. Sponsored by Alkermes, Inc., it has been updated 9 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2019 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alkermes, Inc.
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bangalore, India , Baton Rouge, United States , Berlin, Germany , Budapest, Hungary , Catania, Italy , Changhua, Taiwan , Charleston, United States , Coimbra, Portugal , Dresden, Germany , Erlangen, Germany and 33 more locations